Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen

NCT ID: NCT00069745

Last Updated: 2012-08-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Study Classification

INTERVENTIONAL

Study Start Date

2003-09-30

Study Completion Date

2007-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

PURPOSE:

The SPARC trial is designed to compare the combination of the investigational oral cytotoxic drug, satraplatin, and prednisone, versus prednisone alone as second line chemotherapy in patients with hormone-refractory prostate cancer (HRPC).

TARGET PATIENT POPULATION:

The SPARC trial is intended for patients who have hormone-refractory prostate cancer (HRPC) and whose disease has progressed after treatment with one chemotherapy regimen. Please refer to the Eligibility Criteria page for the key inclusion and exclusion criteria.

WHAT IS SATRAPLATIN:

Satraplatin is a member of the platinum-based class of chemotherapy drugs. Platinum-based drugs have been clinically proven to be one of the most effective classes of anticancer therapies. Unlike the currently marketed platinum-based drugs, satraplatin can be given orally. Satraplatin is also the only platinum-based drug that has demonstrated efficacy against prostate cancer in a randomized trial.

RATIONALE:

There are currently no approved chemotherapy drugs for the second line treatment of hormone-refractory prostate cancer (HRPC). In a preliminary randomized trial conducted in Europe, the combination of satraplatin and prednisone had superior activity compared to prednisone alone, for the treatment of HRPC patients who had not previously been treated with chemotherapy

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostate Cancer Hormone Refractory Prostate Cancer

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Prostatic Neoplasms Cancer Treatment Protocols Antineoplastic protocols One Prior Cytotoxic Chemotherapy Regimen

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Satraplatin

Intervention Type DRUG

Prednisone

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Stage D2 metastatic prostate cancer
* Progression after one prior chemotherapy
* ECOG Performance status equal / less than 2
* Life expectancy \> 3 months
* Surgical or medical castration
* Adequate bone marrow, hepatic and renal functions
* Informed consent

Exclusion Criteria

* More than one prior chemotherapy
* Prior platinum containing compounds
* Prior malignancy
* Prior significant RT/radionuclide therapy
* Major GI surgery or GI disease affecting absorption
* Disease with contraindication to steroids
* Brain metastases
Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Agennix

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Birmingham Hematology and Oncology

Birmingham, Alabama, United States

Site Status

Birmingham Hematology and Oncology

Birmingham, Alabama, United States

Site Status

Hematology Oncology Associates

Phoenix, Arizona, United States

Site Status

Northern AZ Hematology & Oncology Assoc.

Sedona, Arizona, United States

Site Status

Hematology Oncology Physicians/SMO

Tucson, Arizona, United States

Site Status

Arizona Cancer Center

Tuscon, Arizona, United States

Site Status

California Cancer Center

Fresno, California, United States

Site Status

Pacific Shores Medical Group

Long Beach, California, United States

Site Status

Division of Hematology - Oncology

Los Angeles, California, United States

Site Status

University of California Davis Cancer Center, Division of Hematology-Oncology

Sacramento, California, United States

Site Status

Sharp Healthcare - Clinical Oncology Research

San Diego, California, United States

Site Status

Rocky Mountain Cancer Center - Midtown

Denver, Colorado, United States

Site Status

Hartford Hospital

Hartford, Connecticut, United States

Site Status

DeQuattro Community Cancer Center

Manchester, Connecticut, United States

Site Status

Cancer Centers of Florida-Altamonte

Altamonte Springs, Florida, United States

Site Status

The Center for Hematology Oncology

Boca Raton, Florida, United States

Site Status

Hematology/Oncology Group of South Florida

Miami, Florida, United States

Site Status

Innovative Medical Research of South Florida

Miami Shores, Florida, United States

Site Status

Florida Cancer Institute

New Port Richey, Florida, United States

Site Status

Ocala Oncology Center

Ocala, Florida, United States

Site Status

South Florida Oncology & Hematology

Plantation, Florida, United States

Site Status

Hematology/Oncology Associates of Treasure Coast

Port Saint Lucie, Florida, United States

Site Status

Oncology and Hematology Associates of West Broward P.A.

Tamarac, Florida, United States

Site Status

Decatur Memorial Hospital

Decatur, Illinois, United States

Site Status

Northwest Medical Specialists

Niles, Illinois, United States

Site Status

North Shore Research Association

Skokie, Illinois, United States

Site Status

Central Indiana Cancer Centers

Fishers, Indiana, United States

Site Status

Indiana Hematology Oncology Consultants

Indianapolis, Indiana, United States

Site Status

Central Indiana Cancer Centers

Indianapolis, Indiana, United States

Site Status

Oncology Associates of Cedar Rapids

Cedar Rapids, Iowa, United States

Site Status

Kansas City Cancer Centers - Southwest

Overland Park, Kansas, United States

Site Status

Louisiana Oncology Associates

Lafayette, Louisiana, United States

Site Status

LSU Health Science Center, Stanley S. Scott Cancer Center

New Orleans, Louisiana, United States

Site Status

Maine Center for Cancer Medicine & Blood Disorders

Scarborough, Maine, United States

Site Status

Berkshire Hematology Oncology

Pittsfield, Massachusetts, United States

Site Status

Karmanos Cancer Institute, Wayne State University

Detroit, Michigan, United States

Site Status

Maplewood Cancer Center

Maplewood, Minnesota, United States

Site Status

Virginia Piper Cancer Institute

Minneapolis, Minnesota, United States

Site Status

Missouri Cancer Associates

Columbia, Missouri, United States

Site Status

Capitol Comprehensive Cancer Care Clinic

Jefferson City, Missouri, United States

Site Status

St. Joseph Oncology, Inc.

Saint Joseph, Missouri, United States

Site Status

Hematology/Oncology Consultants, Inc.

St Louis, Missouri, United States

Site Status

Arch Medical Services, Inc.

Washington, Missouri, United States

Site Status

Nebraska Methodist Hospital Cancer Center

Omaha, Nebraska, United States

Site Status

Comprehensive Cancer Centers of Nevada

Las Vegas, Nevada, United States

Site Status

Nevada Cancer Institute

Las Vegas, Nevada, United States

Site Status

New Hampshire Oncology-Hematology PA

Hooksett, New Hampshire, United States

Site Status

Hematology Oncology Associates

Albuquerque, New Mexico, United States

Site Status

Lovelace Sandia Health Systems

Albuquerque, New Mexico, United States

Site Status

Veterans Affairs Medical Center

Albuquerque, New Mexico, United States

Site Status

The University of New Mexico

Albuquerque, New Mexico, United States

Site Status

New Mexico Cancer Care Associates

Santa Fe, New Mexico, United States

Site Status

Albany Regional Cancer Center

Albany, New York, United States

Site Status

New York Oncology Hematology, P.C.

Albany, New York, United States

Site Status

Advanced Oncology Associates

Armonk, New York, United States

Site Status

Roswell Park Cancer Institute

Buffalo, New York, United States

Site Status

Interlakes Oncology Hematology

Canandaigua, New York, United States

Site Status

Columbia Presbyterian Medical Center

New York, New York, United States

Site Status

New York Oncology Hematology

Rexford, New York, United States

Site Status

VA Medical Center Syracuse

Syracuse, New York, United States

Site Status

Raleigh Hematology Oncology Clinic

Cary, North Carolina, United States

Site Status

Piedmont Hematology - Oncology

Winston-Salem, North Carolina, United States

Site Status

Dayton Oncology Hematology

Kettering, Ohio, United States

Site Status

Cancer Care Associates

Oklahoma City, Oklahoma, United States

Site Status

Cancer Care Associates

Tulsa, Oklahoma, United States

Site Status

Willamette Valley Cancer Center

Eugene, Oregon, United States

Site Status

Hematology and Oncology Associates of Northeastern PA / PC

Dunmore, Pennsylvania, United States

Site Status

University of Pennsylvania Abramson Cancer Center

Philadelphia, Pennsylvania, United States

Site Status

University of Pittsburgh Cancer Institute- Hillman Cancer Center

Pittsburgh, Pennsylvania, United States

Site Status

Charleston Cancer Center

Charleston, South Carolina, United States

Site Status

Medical University of South Carolina Hollings Cancer Center

Charleston, South Carolina, United States

Site Status

Cancer Center of the Carolinas, Seneca

Seneca, South Carolina, United States

Site Status

The West Clinic

Memphis, Tennessee, United States

Site Status

Texas Cancer Center

Abilene, Texas, United States

Site Status

Texas Oncology

Arlington, Texas, United States

Site Status

Southwest Regional Cancer Center

Austin, Texas, United States

Site Status

Texas Oncology Cancer Center

Austin, Texas, United States

Site Status

Mamie McFaddin Ward Cancer Center

Beaumont, Texas, United States

Site Status

Texas Onoclogy PA - Bedford

Bedford, Texas, United States

Site Status

Texas Cancer Center at Medical City

Dallas, Texas, United States

Site Status

Texas Oncology, P.A.

Dallas, Texas, United States

Site Status

The Texas Cancer Center

Dallas, Texas, United States

Site Status

TOPA Sammons Cancer Center

Dallas, Texas, United States

Site Status

Texas Cancer Center

Denton, Texas, United States

Site Status

El Paso Cancer Treatment Center

El Paso, Texas, United States

Site Status

Texas Oncology, P.A.

Fort Worth, Texas, United States

Site Status

San Antonio Tumor & Blood Clinic

Fredericksburg, Texas, United States

Site Status

Texas Oncology, P.A.

Garland, Texas, United States

Site Status

Texas Oncology, P.A. - Irving

Irving, Texas, United States

Site Status

Lake Vista Cancer Center

Lewisville, Texas, United States

Site Status

Longview Cancer Center

Longview, Texas, United States

Site Status

S. Texas Cancer Center

McAllen, Texas, United States

Site Status

Texas Cancer Center of Mesquite

Mesquite, Texas, United States

Site Status

Allison Cancer Center

Midland, Texas, United States

Site Status

West Texas Cancer Center

Odessa, Texas, United States

Site Status

Hematology Oncology Associates of South Texas

San Antonio, Texas, United States

Site Status

Tyler Cancer Center

Tyler, Texas, United States

Site Status

Waco Cancer Care Research Center

Waco, Texas, United States

Site Status

Texas Oncology, P.A. - Deke Slayton Cancer Center

Webster, Texas, United States

Site Status

Virginia Oncology Associates

Norfolk, Virginia, United States

Site Status

Onc and Hem Associates of SW VA, Inc.

Salem, Virginia, United States

Site Status

Puget Sound Cancer Center - Edmonds

Edmonds, Washington, United States

Site Status

Cancer Care Northwest-North

Spokane, Washington, United States

Site Status

Northwest Cancer Specialists

Vancouver, Washington, United States

Site Status

Froedtert Memorial Lutheran Hospital

Milwaukee, Wisconsin, United States

Site Status

Hospital Italiano de Buenos Aires

Capital Federal, Buenos Aires, Argentina

Site Status

Clinica Oncologica de Excelencia

Capital Federal, Buenos Aires, Argentina

Site Status

Policlinica Bancaria "9 de Julio" Av. Gaona 2197

Capital Federal, Buenos Aires, Argentina

Site Status

Hospital General de Agudos E. Tornu

Capital Federal, Buenos Aires, Argentina

Site Status

Salisbury Investigaciones Clinicas del Grupo CER S.A.

Quilmes, Buenos Aires, Argentina

Site Status

Hospital Italiano Regional del Sur Dept. Oncology

Bahía Blanca, , Argentina

Site Status

Grupo Plaza Dept. Oncology

Belén de Escobar, , Argentina

Site Status

Instituto Quirúrgico del Callao

Buenos Aires, , Argentina

Site Status

Instituto Alexander Fleming

Buenos Aires, , Argentina

Site Status

Centro Oncológico LALCEC

Concepcion Del Uruguay, Entre Ríos, , Argentina

Site Status

Hospital Italiano de Cordoba Dept. Oncology

Córdoba, , Argentina

Site Status

Unidad Oncologica del Neuquen

Neuquén, , Argentina

Site Status

Caici Dept. Oncology

Rosario, , Argentina

Site Status

Centro Oncologico Rosario

Rosario, , Argentina

Site Status

Centro San Roque

San Miguel de Tucumán, Tucumán, , Argentina

Site Status

Clinical Especializada ISIS

Santa Fe, , Argentina

Site Status

AZ-VUB

Brussels, , Belgium

Site Status

Institut Jules Bordet Service de Chimiothérapie

Brussels, , Belgium

Site Status

Hopital Erasme

Brussels, , Belgium

Site Status

UCLC St. Luc

Brussels, , Belgium

Site Status

Sint Maartenziekenhuis

Kortrijk, , Belgium

Site Status

Clinical Hospital Split Department of Oncology and Radiotherapy

Split, , Croatia

Site Status

Clinical Hostpital Rebro Department of Oncology

Zagreb, , Croatia

Site Status

Institut Bergonié

Bordeaux, , France

Site Status

Centre Georges François Leclerc

Dijon, , France

Site Status

Hôpital de La Tronche - CHU de Grenoble: Departement de cacerologie et d'hematologie

Grenoble, , France

Site Status

Clinique du Mail Service d'Oncologie

Grenoble, , France

Site Status

Centre Hospitalier Départemental

La Roche-sur-Yon, , France

Site Status

CHU de Bicêtre

Le Kremlin-Bicêtre, , France

Site Status

Chu Dupuytren

Limoges, , France

Site Status

CRLC Léon Bérard

Lyon, , France

Site Status

Centre Hospitalier Belfort-Montbeliard

Montbéliard, , France

Site Status

CRLC Val d'Aurelle Paul-Lamarque

Montpellier, , France

Site Status

Centre Antoine Lacassagne Oncologie medicale

Nice, , France

Site Status

Hôpital Saint-Louis: Service de Radiotherapy

Paris, , France

Site Status

Hôpital Tenon

Paris, , France

Site Status

CHU de Poitiers

Poitiers, , France

Site Status

Institut Jean , Service d'Oncologie

Reims, , France

Site Status

Centre Eugene Marquis

Rennes, , France

Site Status

Centre Alexis Vautrin

Vandœuvre-lès-Nancy, , France

Site Status

RWTH Aachen

Aachen, , Germany

Site Status

Vivantes Krankenhaus am Urban

Berlin, , Germany

Site Status

Fach- und Belegarzte fur Urologie

Berlin, , Germany

Site Status

Diakonissenkrankenhaus Dessau gGmbH

Dessau, , Germany

Site Status

Universitätsklinikum der Carl-Gustav-Carus Universität

Dresden, , Germany

Site Status

Stadtische Klinicen Frankfurt a.M. Hochst

Frankfurt a.M. Hochst, , Germany

Site Status

EuromedClinic

Fürth, , Germany

Site Status

Klinikum der medizinischen Fakultät der Martin-Luther-Universität Halle-Wittenberg

Halle, , Germany

Site Status

Niedergelassener Urologe

Hamburg, , Germany

Site Status

Medizinische Hochschule

Hanover, , Germany

Site Status

Marienhospital II

Herne, , Germany

Site Status

Universitatklinikum Schleswig-Holstein

Lübeck, , Germany

Site Status

Klinickum der Johannes-Gutenberg Universitat

Mainz, , Germany

Site Status

Klinikum der Philipps - Universitat Marburg

Marburg, , Germany

Site Status

Klinikum rechts der Isar

München, , Germany

Site Status

Universitatklinikum Munster

Münster, , Germany

Site Status

Klinik Bad Trissel

Oberaudorf, , Germany

Site Status

Urologische Praxis

Saarbrücken, , Germany

Site Status

St. Margit Hospital

Budapest, , Hungary

Site Status

St. Istvan Hospital

Budapest, , Hungary

Site Status

National Institute of Oncology

Budapest, , Hungary

Site Status

Pecs Medical University

Pécs, , Hungary

Site Status

Soroka Medical Center

Beerhseva, , Israel

Site Status

Rambam Medical Center

Haifa, , Israel

Site Status

Hadassah University

Jerusalem, , Israel

Site Status

Hospital Ein Kerem Asaf Harofeh Medical Center

Ẕerifin, , Israel

Site Status

Istituto Nazionale per la Ricerca sul Cancro (IST)

Genoa, , Italy

Site Status

Universita degli Studi di Napoli Federico II-Nuovo Policlinico

Napoli, , Italy

Site Status

A.S.O. San Luigi

Orbassano, , Italy

Site Status

Azienda Ospedaliera di Padova

Padua, , Italy

Site Status

A.O. San Camillo-Forlanini

Rome, , Italy

Site Status

Istituto Clinico Humanitas: Dipartimento di Oncologia Medica ed Ematologia

Rozanno (MI), , Italy

Site Status

Academic Hospital of the University of Amsterdam

Amsterdam, , Netherlands

Site Status

Academisch Ziekenhuis Nijmegen: Urology Department

Nijmegen, , Netherlands

Site Status

Streekziekenhuis Koningin : Dept. Urology

Winterswijk, , Netherlands

Site Status

Essalud Dept. Oncology

Jesus Maria, , Peru

Site Status

San Felipe (Oncomedical)

Lima, , Peru

Site Status

INEN Dept Onco-Hemato

Lima, , Peru

Site Status

Oddzial Chemioterapii, Bialostocki Osrodek Onkologiczny

Bialystok, , Poland

Site Status

Oddzial Onkologii I Radioterapii, Szpital Morski im. PCK

Gdynia, , Poland

Site Status

Akademia Medyczna w Lodzi

Lodz, , Poland

Site Status

Akademia Medyczna w Lublinie

Lublin, , Poland

Site Status

Oddzial Radioterapii, Wielkopolskie Centrum Onkologii - Instytut

Poznan, , Poland

Site Status

Akademia Medyczna w Szczecinie

Szczecin, , Poland

Site Status

Klinika Nowotworow Ukladu Moczowego, Centrum Onkologii - Instytut

Warsaw, , Poland

Site Status

Oddzial Chemioterapii, 4 Wojskowy Szpital Kliniczny

Wroclaw, , Poland

Site Status

N.N Blokchin Cancer Research Centre

Moscow, , Russia

Site Status

Hertzen Research Institute of Oncology

Moscow, , Russia

Site Status

Medical Radilogical Research Center of Rams

Obninsk, , Russia

Site Status

Hospital de la Santa Creu i Sant Pau, Sevicio de Oncología Médica

Barcelona, , Spain

Site Status

Hospital Clinic i Provincial, Sevicio de Oncología Médica

Barcelona, , Spain

Site Status

Hospital Ramon y Cajal

Madrid, , Spain

Site Status

Hospital Clínico San Carlos, Sevicio de Oncología Médica

Madrid, , Spain

Site Status

Clinica Universitaria de Navarra, Sevicio de Oncología Médica

Pamplona, , Spain

Site Status

Hospital Universitario Marqués de Valdecilla, Sevicio de Oncología Médica

Santander, , Spain

Site Status

Instituto Valenciano de Oncología: Sevicio de Oncología Médica

Valencia, , Spain

Site Status

Aberdeen Royal Infirmary

Aberdeen, , United Kingdom

Site Status

CRUK Institute for Cancer Studies

Birmingham, , United Kingdom

Site Status

Bristol Oncology Centre

Bristol, , United Kingdom

Site Status

Beatson Oncology Center

Glasgow, , United Kingdom

Site Status

Guy's hospital

London, , United Kingdom

Site Status

St George's Healthcare Dept of Oncology, Tooting

London, , United Kingdom

Site Status

St. Bartholomew's Hospital Dept. of Medical Oncology

London, , United Kingdom

Site Status

Northern Centre for Cancer Treatment

Newcastle upon Tyne, , United Kingdom

Site Status

Lister Hospital Department of Urology

Stevenage Hertfordshire, , United Kingdom

Site Status

Royal Marsden Hospital

Sutton, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Belgium Croatia France Germany Hungary Israel Italy Netherlands Peru Poland Russia Spain United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

GPC SAT3-03-01

Identifier Type: -

Identifier Source: org_study_id